Press Releases Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
16.38 ^USD	-0.18%		-6.77%	+12.19%

05-07	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	MT
05-06	Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Day One Reports First Quarter 2024 Financial Results and Corporate Progress	05-06	GL
Day One Biopharmaceuticals : Corporate Presentation - April 2024	04-24	PU
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	04-23	GL
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	04-23	AQ
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress	02-26	GL
Day One Announces Two New Appointments to Board of Directors	01-17	GL
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference	12-19	GL
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine	11-17	GL
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine	11-17	AQ
Day One Biopharmaceuticals : Change in Certifying Accountants - Form 8-K	11-15	PU
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference	11-14	GL
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress	11-06	GL
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress	11-06	AQ
Day One Biopharmaceuticals : Corporate Presentation - October 2023	30/10/23	PU
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	30/10/23	GL
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	30/10/23	AQ
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	11/09/23	GL
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience	16/08/23	GL
Sprint Bioscience licenses the VADA (VRK1) program to Day One Biopharmaceuticals	16/08/23	AQ
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience	16/08/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Press Releases

Filters